コンパニオン診断薬の世界市場

コンパニオン診断薬の世界市場は2030年までに154億米ドルに達する見込み

2023年に133億米ドルと推定されたコンパニオン診断薬の世界市場は、2030年には154億米ドルに達し、分析期間2023～2030年のCAGRは2.1%で成長すると予測されます。コンパニオン診断薬アッセイキット＆試薬は、本レポートで分析したセグメントの1つであり、CAGRは1.4％を記録し、分析期間終了時には97億米ドルに達すると予測されます。コンパニオン診断薬ソフトウェア＆サービスセグメントの成長率は、分析期間でCAGR 3.5％と推定されます。

米国市場は36億米ドル、中国はCAGR 1.5％で成長予測

米国のコンパニオン診断薬市場は2023年に36億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに24億米ドルの市場規模に達すると予測され、分析期間2023～2030年のCAGRは1.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.5％と0.0％と予測されています。欧州では、ドイツがCAGR-1.5%程度で成長すると予測されています。

コンパニオン診断薬-主要動向と促進要因

コンパニオン診断薬はプレシジョンメディシンの不可欠な要素であり、患者固有の遺伝子構成やその他のバイオマーカーに基づいて個々の患者に適した治療を特定するように設計されています。これらの診断試験は、がん患者にとって最も効果的な治療法を決定するのに役立つものであり、患者の腫瘍の分子プロファイルに合わせた治療を保証するものです。個別化された治療計画を可能にすることで、コンパニオン診断薬は治療の有効性と安全性を改善し、副作用を減らし、最終的に患者の転帰を向上させる。コンパニオン診断薬は、特定の治療製品から最も恩恵を受ける可能性の高い患者を特定し、適切な薬剤が適切な患者に適切なタイミングで投与されるようにすることで機能します。このアプローチは、治療の情勢を一変させ、画一的なモデルから、より的を絞った個別化治療へと移行しつつあります。

分子診断学とゲノミクスの技術的進歩は、コンパニオン診断薬の進化を大きく後押ししています。次世代シーケンシング（NGS）とポリメラーゼ連鎖反応（PCR）は、コンパニオン診断薬の精度とスピードを向上させた重要な技術の一つです。これらの技術により、包括的なゲノムプロファイリングが可能となり、様々な疾患、特にがんに関連する遺伝子変異や変化を正確に検出することができます。さらに、データ解析における人工知能（AI）と機械学習の統合は、これらの診断の精度をさらに向上させ、より正確で信頼性の高い結果を可能にしました。複数のバイオマーカーを同時に検出できるマルチプレックスアッセイの開発も、コンパニオン診断薬の範囲と効率を拡大しています。このような技術の進歩は、診断能力を向上させるだけでなく、製薬会社と診断薬メーカーが医薬品やコンパニオンテストを共同開発するためのコラボレーションを促進し、患者への個別化治療の提供を加速させています。

コンパニオン診断薬市場の成長は、いくつかの要因によって牽引されています。がんやその他の慢性疾患の有病率の増加により、標的治療の開発が必要となり、コンパニオン診断薬の需要が高まっています。FDAなどの規制機関は、医薬品承認プロセスにおけるコンパニオン診断薬の重要性を強調し、製薬会社がこれらの試験を臨床開発戦略に取り入れるよう促しています。プレシジョンメディシンの台頭や個別化治療アプローチの採用拡大も市場の成長を後押ししています。さらに、NGSやデジタルPCRなどの分子診断技術の進歩により、コンパニオン診断薬の精度と効率が向上し、より利用しやすく信頼性の高いものになっています。バイオマーカー探索の拡大と医薬品開発におけるバイオマーカーの利用の増加は、市場に新たな機会を生み出しています。さらに、診断会社と製薬会社のコラボレーションがイノベーションを促進し、新しいコンパニオン診断薬の開発を加速しています。これらの要因が総合的に、コンパニオン診断薬の力強い成長と普及に寄与し、個別化医療の展望を変え、患者のケアを向上させています。

調査対象企業の例（全47件）

• Abbott Molecular
• Agilent Technologies, Inc.
• bioMerieux SA
• Cepheid
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Foundation Medicine Inc.
• Laboratory Corporation of America（R）Holdings
• Leica Biosystems Nussloch GmbH
• Merck & Co. Inc.
• Myriad Genetics Inc.
• NeoGenomics Laboratories, Inc.
• QIAGEN N.V.
• Quest Diagnostics Inc.
• Thermo Fischer Scientific Inc.

目次

第1章 調査手法

第2章 エグゼクティブ概要

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の展望

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他の欧州
• アジア太平洋
• その他

第4章 競合

Global Companion Diagnostics Market to Reach US$15.4 Billion by 2030

The global market for Companion Diagnostics estimated at US$13.3 Billion in the year 2023, is expected to reach US$15.4 Billion by 2030, growing at a CAGR of 2.1% over the analysis period 2023-2030. Companion Diagnostics Assay kits & Reagents, one of the segments analyzed in the report, is expected to record a 1.4% CAGR and reach US$9.7 Billion by the end of the analysis period. Growth in the Companion Diagnostics Software & Services segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 1.5% CAGR

The Companion Diagnostics market in the U.S. is estimated at US$3.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 1.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.5% and 0.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately -1.5% CAGR.

Companion Diagnostics - Key Trends and Drivers

Companion diagnostics are an integral component of precision medicine, designed to identify the suitability of specific treatments for individual patients based on their unique genetic makeup or other biomarkers. These diagnostic tests are critical in the field of oncology, where they help determine the most effective therapies for cancer patients, ensuring treatments are tailored to the molecular profile of a patient's tumor. By enabling personalized treatment plans, companion diagnostics improve the efficacy and safety of therapies, reduce adverse effects, and ultimately enhance patient outcomes. They work by identifying patients who are most likely to benefit from a particular therapeutic product, ensuring that the right drug is administered to the right patient at the right time. This approach is transforming the landscape of medical treatment, moving away from the one-size-fits-all model to more targeted and individualized care.

The technological advancements in molecular diagnostics and genomics are significantly driving the evolution of companion diagnostics. Next-generation sequencing (NGS) and polymerase chain reaction (PCR) are among the key technologies that have enhanced the precision and speed of companion diagnostics. These technologies enable comprehensive genomic profiling and accurate detection of genetic mutations and alterations associated with various diseases, particularly cancer. Additionally, the integration of artificial intelligence (AI) and machine learning in data analysis has further refined the accuracy of these diagnostics, allowing for more precise and reliable results. The development of multiplex assays, which can detect multiple biomarkers simultaneously, has also expanded the scope and efficiency of companion diagnostics. This technological progress is not only improving diagnostic capabilities but also fostering collaborations between pharmaceutical companies and diagnostic manufacturers to co-develop drugs and companion tests, thereby accelerating the delivery of personalized therapies to patients.

The growth in the companion diagnostics market is driven by several factors. The increasing prevalence of cancer and other chronic diseases necessitates the development of targeted therapies, which in turn boosts the demand for companion diagnostics. Regulatory agencies, such as the FDA, are emphasizing the importance of companion diagnostics in the drug approval process, encouraging pharmaceutical companies to incorporate these tests into their clinical development strategies. The rise of precision medicine and the growing adoption of personalized treatment approaches are also propelling market growth. Furthermore, advancements in molecular diagnostics technologies, such as NGS and digital PCR, are enhancing the accuracy and efficiency of companion diagnostics, making them more accessible and reliable. The expansion of biomarker discovery and the increasing use of biomarkers in drug development are generating new opportunities for the market. Additionally, the collaboration between diagnostic companies and pharmaceutical firms is fostering innovation and accelerating the development of new companion diagnostics. These factors collectively contribute to the robust growth and widespread adoption of companion diagnostics, transforming the landscape of personalized medicine and improving patient care.

Select Competitors (Total 47 Featured) -

• Abbott Molecular
• Agilent Technologies, Inc.
• bioMerieux SA
• Cepheid
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Foundation Medicine Inc.
• Laboratory Corporation of America(R) Holdings
• Leica Biosystems Nussloch GmbH
• Merck & Co. Inc.
• Myriad Genetics Inc.
• NeoGenomics Laboratories, Inc.
• QIAGEN N.V.
• Quest Diagnostics Inc.
• Thermo Fischer Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Companion Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Technological Advancements in Molecular Diagnostics Propel Growth in the Companion Diagnostics Market
  • Integration of Next-Generation Sequencing (NGS) and PCR Expands Addressable Market Opportunity
  • Rising Adoption of Precision Medicine Throws the Spotlight on Personalized Treatment Approaches
  • Development of Multiplex Assays Drives Efficiency and Market Expansion
  • AI and Machine Learning in Data Analysis Strengthen Business Case for Companion Diagnostics
  • Increasing Prevalence of Cancer and Chronic Diseases Generates Demand for Targeted Therapies
  • Regulatory Emphasis on Companion Diagnostics in Drug Approval Processes Propels Market Growth
  • Expansion of Biomarker Discovery Accelerates Demand for Companion Diagnostics
  • Growing Use of Biomarkers in Drug Development Enhances Market Opportunities
  • Rising Investment in Genomic Research Drives Adoption of Companion Diagnostics
  • Digital Transformation in Healthcare Sustains Growth in the Companion Diagnostics Market
  • Personalized Treatment Strategies Promise Improved Patient Outcomes
  • Increasing Accessibility and Affordability of Advanced Diagnostic Technologies Generate Market Growth
  • Evolution of Healthcare Policies and Reimbursement Frameworks Propel Adoption of Companion Diagnostics
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Companion Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World 7-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Assay kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 5: World 7-Year Perspective for Assay kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Software & Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 7: World 7-Year Perspective for Software & Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Polymerase Chain Reaction (PCR) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World 7-Year Perspective for Polymerase Chain Reaction (PCR) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Immunohistochemistry (IHC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 11: World 7-Year Perspective for Immunohistochemistry (IHC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for In Situ Hybridization (ISH) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 13: World 7-Year Perspective for In Situ Hybridization (ISH) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Next-Generation Sequencing (NGS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 15: World 7-Year Perspective for Next-Generation Sequencing (NGS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 17: World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 19: World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 21: World 7-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 23: World 7-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Pharmaceutical & Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 25: World 7-Year Perspective for Pharmaceutical & Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: World 7-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 28: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 29: World 7-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 30: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 31: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: USA 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 34: USA Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 35: USA 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 36: USA Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 37: USA 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: USA 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030
• CANADA
  • TABLE 40: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 41: Canada 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 42: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 43: Canada 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Canada 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 46: Canada Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 47: Canada 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030
• JAPAN
  • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 48: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 49: Japan 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Japan 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 52: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 53: Japan 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 54: Japan Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 55: Japan 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030
• CHINA
  • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 56: China Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 57: China 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 58: China Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 59: China 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 60: China Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 61: China 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 63: China 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030
• EUROPE
  • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 64: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 65: Europe 7-Year Perspective for Companion Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 66: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 67: Europe 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Europe 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 70: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 71: Europe 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 72: Europe Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 73: Europe 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030
• FRANCE
  • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 74: France Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 75: France 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 76: France Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 77: France 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 78: France Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 79: France 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 80: France Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 81: France 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030
• GERMANY
  • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 82: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 83: Germany 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 84: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 85: Germany 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 86: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Germany 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 88: Germany Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 89: Germany 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030
• ITALY
  • TABLE 90: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 91: Italy 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 92: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Italy 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 94: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 95: Italy 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 96: Italy Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 97: Italy 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030
• UNITED KINGDOM
  • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 98: UK Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 99: UK 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 100: UK Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 101: UK 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 102: UK Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 103: UK 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 104: UK Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 105: UK 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030
• REST OF EUROPE
  • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 107: Rest of Europe 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 109: Rest of Europe 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Rest of Europe 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 113: Rest of Europe 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030
• ASIA-PACIFIC
  • Companion Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 115: Asia-Pacific 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 117: Asia-Pacific 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 119: Asia-Pacific 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 121: Asia-Pacific 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030
• REST OF WORLD
  • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Product & Service - Assay kits & Reagents and Software & Services - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 123: Rest of World 7-Year Perspective for Companion Diagnostics by Product & Service - Percentage Breakdown of Value Sales for Assay kits & Reagents and Software & Services for the Years 2024 & 2030
  • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Technology - Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 125: Rest of World 7-Year Perspective for Companion Diagnostics by Technology - Percentage Breakdown of Value Sales for Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Next-Generation Sequencing (NGS) and Other Technologies for the Years 2024 & 2030
  • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by Indication - Oncology, Neurology and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 127: Rest of World 7-Year Perspective for Companion Diagnostics by Indication - Percentage Breakdown of Value Sales for Oncology, Neurology and Other Indications for the Years 2024 & 2030
  • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Companion Diagnostics by End-Use - Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Rest of World 7-Year Perspective for Companion Diagnostics by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biopharmaceutical Companies, Reference Laboratories, CROs and Other End-Uses for the Years 2024 & 2030

IV. COMPETITION